866648-53-5 Usage
General Description
(6-Chloro-2-trifluoromethylpyrimidin-4-yl)dimethylamine is a chemical compound with the molecular formula C7H9ClF3N3. It is a pyrimidine derivative with a chloro and trifluoromethyl group attached at the 6th and 2nd positions, respectively. The compound also contains a dimethylamine group. It is used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its unique structure and reactivity. Additionally, it can be used as an intermediate in the production of other organic compounds. This chemical is considered hazardous and should be handled with care, following proper safety procedures.
Check Digit Verification of cas no
The CAS Registry Mumber 866648-53-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,6,4 and 8 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 866648-53:
(8*8)+(7*6)+(6*6)+(5*6)+(4*4)+(3*8)+(2*5)+(1*3)=225
225 % 10 = 5
So 866648-53-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H7ClF3N3/c1-14(2)5-3-4(8)12-6(13-5)7(9,10)11/h3H,1-2H3
866648-53-5Relevant articles and documents
PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF
-
Page/Page column 140; 141, (2008/06/13)
The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.